US Stock MarketDetailed Quotes

Acrivon Therapeutics (ACRV)

Watchlist
  • 1.620
  • +0.010+0.62%
Close Mar 13 15:59 ET
  • 1.600
  • -0.020-1.23%
Post 19:39 ET
51.12MMarket Cap-0.76P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Acrivon Therapeutics (ACRV) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2025
(Q2)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
-21.69%19.69M
5.65%22.65M
22.61%21.66M
32.93%89.2M
18.53%24.95M
55.79%25.14M
38.13%21.44M
22.75%17.67M
105.48%67.1M
111.69%21.05M
Selling and administrative expenses
-3.78%6.04M
0.86%6.47M
0.86%6.25M
19.58%25.21M
13.43%6.32M
6.92%6.28M
28.27%6.41M
33.66%6.2M
142.06%21.08M
36.54%5.58M
-General and administrative expense
-3.78%6.04M
0.86%6.47M
0.86%6.25M
19.58%25.21M
13.43%6.32M
6.92%6.28M
28.27%6.41M
33.66%6.2M
142.06%21.08M
36.54%5.58M
Research and development costs
-27.65%13.65M
7.70%16.18M
34.35%15.41M
39.04%63.99M
20.36%18.63M
83.73%18.86M
42.81%15.03M
17.58%11.47M
92.18%46.02M
164.04%15.48M
Operating profit
21.69%-19.69M
-5.65%-22.65M
-22.61%-21.66M
-32.93%-89.2M
-18.53%-24.95M
-55.79%-25.14M
-38.13%-21.44M
-22.75%-17.67M
-105.48%-67.1M
-111.69%-21.05M
Net non-operating interest income expense
-44.18%1.51M
-35.78%1.73M
38.04%2M
30.75%9.2M
39.66%2.36M
52.60%2.7M
52.20%2.69M
-19.98%1.45M
7.04M
1.69M
Non-operating interest income
-44.18%1.51M
-35.78%1.73M
38.04%2M
30.75%9.2M
39.66%2.36M
52.60%2.7M
52.20%2.69M
-19.98%1.45M
--7.04M
--1.69M
Other net income (expense)
-5,400.00%-53K
-58.18%-87K
94.70%-14K
-73.29%-558K
-320.18%-240K
101.03%1K
66.46%-55K
-55.29%-264K
-121.61%-322K
-89.27%109K
Other non- operating income (expenses)
-5,400.00%-53K
-58.18%-87K
94.70%-14K
-73.29%-558K
-320.18%-240K
101.03%1K
66.46%-55K
-55.29%-264K
-121.61%-322K
-89.27%109K
Income before tax
18.75%-18.23M
-11.75%-21.01M
-19.37%-19.68M
-33.40%-80.56M
-18.59%-22.83M
-55.13%-22.44M
-35.10%-18.8M
-29.24%-16.49M
-93.76%-60.39M
-115.61%-19.25M
Income tax
Net income
18.75%-18.23M
-11.75%-21.01M
-19.37%-19.68M
-33.40%-80.56M
-18.59%-22.83M
-55.13%-22.44M
-35.10%-18.8M
-29.24%-16.49M
-93.76%-60.39M
-115.61%-19.25M
Net income continuous Operations
18.75%-18.23M
-11.75%-21.01M
-19.37%-19.68M
-33.40%-80.56M
-18.59%-22.83M
-55.13%-22.44M
-35.10%-18.8M
-29.24%-16.49M
-93.76%-60.39M
-115.61%-19.25M
Minority interest income
Net income attributable to the parent company
18.75%-18.23M
-11.75%-21.01M
-19.37%-19.68M
-33.40%-80.56M
-18.59%-22.83M
-55.13%-22.44M
-35.10%-18.8M
-29.24%-16.49M
-93.76%-60.39M
-115.61%-19.25M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
18.75%-18.23M
-11.75%-21.01M
-19.37%-19.68M
-33.40%-80.56M
-18.59%-22.83M
-55.13%-22.44M
-35.10%-18.8M
-29.24%-16.49M
-93.76%-60.39M
-115.61%-19.25M
Basic earnings per share
20.34%-0.47
-5.77%-0.55
30.14%-0.51
13.14%-2.38
31.03%-0.6
10.61%-0.59
17.46%-0.52
-25.86%-0.73
63.76%-2.74
-8.75%-0.87
Diluted earnings per share
20.34%-0.47
-5.77%-0.55
30.14%-0.51
13.14%-2.38
31.03%-0.6
10.61%-0.59
17.46%-0.52
-25.86%-0.73
63.76%-2.74
-8.75%-0.87
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2025(Q2)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense -21.69%19.69M5.65%22.65M22.61%21.66M32.93%89.2M18.53%24.95M55.79%25.14M38.13%21.44M22.75%17.67M105.48%67.1M111.69%21.05M
Selling and administrative expenses -3.78%6.04M0.86%6.47M0.86%6.25M19.58%25.21M13.43%6.32M6.92%6.28M28.27%6.41M33.66%6.2M142.06%21.08M36.54%5.58M
-General and administrative expense -3.78%6.04M0.86%6.47M0.86%6.25M19.58%25.21M13.43%6.32M6.92%6.28M28.27%6.41M33.66%6.2M142.06%21.08M36.54%5.58M
Research and development costs -27.65%13.65M7.70%16.18M34.35%15.41M39.04%63.99M20.36%18.63M83.73%18.86M42.81%15.03M17.58%11.47M92.18%46.02M164.04%15.48M
Operating profit 21.69%-19.69M-5.65%-22.65M-22.61%-21.66M-32.93%-89.2M-18.53%-24.95M-55.79%-25.14M-38.13%-21.44M-22.75%-17.67M-105.48%-67.1M-111.69%-21.05M
Net non-operating interest income expense -44.18%1.51M-35.78%1.73M38.04%2M30.75%9.2M39.66%2.36M52.60%2.7M52.20%2.69M-19.98%1.45M7.04M1.69M
Non-operating interest income -44.18%1.51M-35.78%1.73M38.04%2M30.75%9.2M39.66%2.36M52.60%2.7M52.20%2.69M-19.98%1.45M--7.04M--1.69M
Other net income (expense) -5,400.00%-53K-58.18%-87K94.70%-14K-73.29%-558K-320.18%-240K101.03%1K66.46%-55K-55.29%-264K-121.61%-322K-89.27%109K
Other non- operating income (expenses) -5,400.00%-53K-58.18%-87K94.70%-14K-73.29%-558K-320.18%-240K101.03%1K66.46%-55K-55.29%-264K-121.61%-322K-89.27%109K
Income before tax 18.75%-18.23M-11.75%-21.01M-19.37%-19.68M-33.40%-80.56M-18.59%-22.83M-55.13%-22.44M-35.10%-18.8M-29.24%-16.49M-93.76%-60.39M-115.61%-19.25M
Income tax
Net income 18.75%-18.23M-11.75%-21.01M-19.37%-19.68M-33.40%-80.56M-18.59%-22.83M-55.13%-22.44M-35.10%-18.8M-29.24%-16.49M-93.76%-60.39M-115.61%-19.25M
Net income continuous Operations 18.75%-18.23M-11.75%-21.01M-19.37%-19.68M-33.40%-80.56M-18.59%-22.83M-55.13%-22.44M-35.10%-18.8M-29.24%-16.49M-93.76%-60.39M-115.61%-19.25M
Minority interest income
Net income attributable to the parent company 18.75%-18.23M-11.75%-21.01M-19.37%-19.68M-33.40%-80.56M-18.59%-22.83M-55.13%-22.44M-35.10%-18.8M-29.24%-16.49M-93.76%-60.39M-115.61%-19.25M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 18.75%-18.23M-11.75%-21.01M-19.37%-19.68M-33.40%-80.56M-18.59%-22.83M-55.13%-22.44M-35.10%-18.8M-29.24%-16.49M-93.76%-60.39M-115.61%-19.25M
Basic earnings per share 20.34%-0.47-5.77%-0.5530.14%-0.5113.14%-2.3831.03%-0.610.61%-0.5917.46%-0.52-25.86%-0.7363.76%-2.74-8.75%-0.87
Diluted earnings per share 20.34%-0.47-5.77%-0.5530.14%-0.5113.14%-2.3831.03%-0.610.61%-0.5917.46%-0.52-25.86%-0.7363.76%-2.74-8.75%-0.87
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--
Market Insights
Nancy Pelosi Portfolio
No. Symbol % Chg
Sample Name
Sample Code
 +1.24%
Sample Name
Sample Code
 +1.20%
Sample Name
Sample Code
 +1.06%
4
Tempus AI
TEM
+0.91%
5
Roblox
RBLX
+0.21%
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +22.59%
Sample Name
Sample Code
 +15.30%
Sample Name
Sample Code
 +12.93%
4
ZTO Express
ZTO
+5.44%
5
GDS Holdings
GDS
+4.87%
View More
Middle East conflict spreads to the stock market! How should investors respond?
Recently, the ongoing conflict between the US and Iran has continued to disrupt the stock market. On March 11 local time, Trump once again s Show More
Breaking! The US and Israel jointly bombed Iran. What will be the stock market trend next week?
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.

- No more -